Truffle Capital, an investor in Deinove, is a European private equity firm originally set up for investments in spin-offs from companies active in the IT, Energy, and Life Sciences sectors.
-
Deinove is a December 2006 spin-off from Institut Necker / Université Paris V / Institut Européen de Technologie de Paris. Deinove is centered on the exploitation of a breakthrough discovery: the molecular mechanism allowing a bacterium, (Deinoccocus Radiodurans) to resuscitate following destruction of its genome.
-
It has potential applications in of creating novel genomes and viable bacteria functions useful in biomass processing for biofuels.
-
Following a €0.4 million seed financing by Truffle Capital in 2006, the company will assess and prioritize key potential applications and R&D projects within the next 9 months.
-
Truffle Capital board members: Philippe Pouletty, M.D., Jean François Fourt.